Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...